Proactive - Interviews for investors

Sunstone Metals Ltd (ASX:STM) managing director Patrick Duffy joins Proactive’s Tylah Tully to discuss the new discovery of a new gold-copper porphyry, the Copete target, at the Bramaderos Project in southern Ecuador.

This discovery expands the mineralised area to a 2-kilometre by 1.8-kilometre cluster, supporting the potential for a large open-pit mining operation.

The Copete target complements an earlier porphyry exploration target estimate of 3.3-8.6 million ounces of gold equivalent, indicating room for an increase in the target.

Duffy says Copete is strategically located near the 2.7 million-ounce Brama-Alba resource and the Melonal exploration target, strengthening Bramaderos' potential as a world-class, long-term mining prospect.

Initial trench sampling at Copete has revealed substantial surface mineralisation, with one trench returning 113 metres at 0.64 g/t gold equivalent.

The Copete target features a 1.8-kilometre mineralised trend and shares characteristics with the Brama deposit, showing potential for higher-grade copper at depth.

Although largely unexplored, Copete’s magnetic and structural features suggest it represents an intact porphyry system.

Partnership discussions are underway with third parties to expedite exploration and resource growth for Bramaderos and Sunstone other Ecuador project, El Palmar.

#ProactiveInvestors #SunstoneMetals #ASX #BramaderosProject, #GoldCopper, #EcuadorMining, #ResourceDiscovery, #MineralExploration, #MiningInvestment, #OpenPitMining, #CopperGold, #PorphyrySystem, #ExplorationTarget, #NaturalResources, #MiningProjects, #MiningPotential, #MineralisedCluster, #CopeteDiscovery, #PartnershipDiscussions, #ElPalmarProject, #WorldClassResources, #MiningNews

International Graphite Ltd (ASX: IG6) managing director and CEO Andrew Worland talks with Proactive’s Tylah Tully about the company's progress following a $4.5 million grant from the Western Australian Government.

The grant is part of a $6.5 million funding initiative, primarily supporting the development of Australia’s first commercial graphite facility in Collie, WA.

Worland shared details on how the funding aligns with International Graphite's expansion strategy, starting with the construction of a 3,000-tonne production facility.

He explained, "This funding agreement is really the mechanism that fully funds our stage one development."

The state-backed initiative allows the company to continue developing its graphite production capacity, keeping shareholder dilution minimal and focusing on creating sustainable market entry points for battery anode materials.

Looking ahead, Worland noted that production could expand up to 10,000 tonnes annually, establishing International Graphite as a notable supplier outside of China.

He highlighted the support from the WA Government as "fantastic news for us" and outlined how this partnership mitigated risk and enabled steady project financing based on clear milestones.

Beyond Collie, the company is actively advancing its Springdale Project, which recently obtained a second mining lease, unlocking one of Australia's largest graphite resources.

This exciting phase in International Graphite’s journey reflects broader growth in the battery materials market, which Worland described as driven by rising demand for electric vehicles and lithium-ion battery components.

#ProactiveInvestors #InternationalGraphite #ASX #IG6 #GraphiteProduction #BatteryMaterials #WesternAustralia #CollieGraphitePlant #BatteryAnodes #MiningNews #AndrewWorland #ElectricVehicles #ProactiveStudio

Seeing Machines Ltd (AIM:SEE, OTC:SEEMF) CEO Paul McGlone and CFO Martin Ive sat down with Proactive’s Tylah Tully to discuss the company’s FY24 results and quarterly KPIs.

McGlone emphasised Seeing Machines’ automotive expansion, stating, “Greater than 2.6 million cars on the road, eight programs in production…demonstrates our ability to get programs over the line.”

This quarter alone, the company reported over 405,000 vehicles, representing a 100% increase year-over-year.

The executives also explained changes to KPI metrics due to a new agreement with Caterpillar, including a one-time $16.5 million payment, which led to the removal of Caterpillar’s sales volume from Seeing Machines’ KPIs.

McGlone noted that emphasising “hardware sales and annual recurring revenue” will help shareholders more clearly understand Seeing Machines’ growth and margin profile.

Ive highlighted the company’s ongoing efforts toward cash flow break-even, with plans for cost reduction and strategic cash flow management.

While acknowledging industry volatility, Seeing Machines is optimistic for the future due to strong automotive penetration rates, regulatory-driven demand and forward-looking production timelines.

“Our focus is on increasing revenue, royalties, and margins, supported by a lower cost base,” McGlone said.

#ProactiveInvestors #SeeingMachines #AIM #SEE #SEEMF #OTC #AutomotiveIndustry #KPI #FinancialResults #PaulMcGlone #MartinIve #RevenueGrowth #ProactiveInvestors #FinancialOutlook #AutomotiveGrowth #Caterpillar #Investing

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) CEO James Graham joins Proactive’s Tylah Tully to discuss the ethics approval the company has received for a Phase 3 Clinical Trial of RECCE® 327.

Recce has received Human Research Ethics Committee approval has been received to begin dosing in Indonesia for a Registrational Phase 3 clinical trial for its RECCE® 327 (R327G) topical gel, designed to treat diabetic foot infections (DFIs).

The large-scale, double-blinded, placebo-controlled trial, set to commence in mid-December, will involve up to 300 patients across Indonesia, with a 12-month study period. Results are anticipated by late 2025, with regulatory approval and commercial launch aimed for H1 2026.

The trial, supported by the Australian and Indonesian governments and facilitated by PT Etana Biotechnologies, represents a critical step in bringing R327G to market.

With an estimated cost of US$2 million, the trial will benefit from Australia’s R&D rebate scheme, reducing financial strain. Approval from BPOM, Indonesia’s food and drug authority, is expected soon.

The trial capitalises on Indonesia’s high diabetes prevalence and growing antimicrobial resistance needs. Approval in Indonesia could pave the way for further regulatory acceptance across ASEAN countries. Initial trials in Australia showed a 100% patient response rate, underscoring the potential of R327G to address severe infections in diabetic foot ulcers.

Recce has also reported significant progress in its Phase II clinical trial for R327G to treat Acute Bacterial Skin and Skin Structure Infections (ABSSSI). With 20 of the 30 patients now dosed, the trial shows promising results, as all dosed patients have met the primary endpoints of either a cure or marked improvement without any Serious Adverse Events (SAEs) reported.

The trial is set for completion by the end of 2024, reinforcing the potential of R327G in addressing critical unmet needs in bacterial infection treatment. The product’s development trajectory is strengthened by previous regulatory endorsements and encouraging interim data, indicating a strong efficacy and safety profile.

#ProactiveInvestors #ReccePharmaceuticals #ASX #DiabeticFootInfections #RECCE327 #Phase3Trial #EthicsApproval #Indonesia #ClinicalTrials #DiabetesTreatment #AntiInfective #HealthcareInnovation #Biotechnology #Diabetes #ASEAN #RDEntitlement #InfectionPrevention #MedicalResearch #DFI #TopicalGel #IndonesianHealth #BiotechIndustry

Nexus Minerals Ltd (ASX: NXM) managing director Andy Tudor joins Proactive’s Tylah Tully to discuss the results from its latest drilling campaign at the Wallbrook Gold Project.

It has completed a 284-hole, 9,811-metre aircore drill program across four targets in the project in the north-eastern Goldfields of Western Australia.

Each target delivered promising high-grade, near-surface gold assay results, supporting Nexus’s focus on shallow, accessible discoveries.

Payns Prospect (MC5.2 and MC5.1): The new Payns Prospect, combining MC5.2 and MC5.1 targets, delivered high-grade assays such as 4 metres at 6.85 g/t gold within 16 metres at 2.74 g/t from 28 metres. The target, near the Million Dollar Gold Mine, shows potential for extensive mineralisation, with continuity in grade and width over a 750-metre area.

Godfrey Prospect (MC2.2): Positioned east of the Crusader-Templar Deposit, Godfrey returned strong grades with results like 4 metres at 4.02 g/t gold within 15 metres at 1.30 g/t from 24 metres. This target exhibits a significant 1,200 x 100-metre gold system, showing continuity and warranting future reverse circulation (RC) drilling.

Target MC2.1: Adjacent to Wallbrook Gold Mine, MC2.1 returned high-grade intercepts, such as 8 metres at 2.94 g/t gold within 28 metres at 1.13 g/t from 44 metres, suggesting a 400 x 250-metre anomaly. Further aircore drilling is planned to assess connection with the Clement Prospect.

Target MC1.5: Located on the Wallbrook Monzonite's western contact, MC1.5 produced notable results, including 4 metres at 10.95 g/t gold within 15 metres at 3.65 g/t from 16 metres. This high-grade target aligns with a fertile structural trend and will undergo RC drill testing in future campaigns.

Nexus plans additional aircore drilling to expand and validate these targets before progressing to more extensive RC drilling, with significant potential to grow the project’s resource base.

#ProactiveInvestors #ASX #NexusMinerals #GoldExploration #WallbrookGoldProject #AircoreDrilling #GoldDiscovery #PaynsProspect #GodfreyProspect #WesternAustralia #MineralExploration #HighGradeGold #ASX #GoldMining #MiningNews #DrillResults #Geology #ResourceExpansion #MiningInvesting #PreciousMetals #ExplorationSuccess #GoldAssays

Imugene Ltd (ASX:IMU, OTC:IUGNF) managing director and CEO Leslie Chong joins Proactive’s Tylah Tully to provide a company update, including launching the first Australian site for the Phase 1b clinical trial of its azer-cel (azercabtagene zapreleucel) allogeneic CAR T-cell therapy.

The Royal Prince Alfred Hospital in Sydney will lead Australian patient recruitment, with enrolment beginning in November 2024, marking Australia’s only active trial for allogeneic CAR T-cell therapy in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

This Australian expansion offers patients access to azer-cel, addressing critical treatment gaps for DLBCL, an aggressive form of non-Hodgkin’s lymphoma.

Chong emphasised the importance of local access to this innovative therapy.

Imugene’s US trials have shown promising results, with three patients achieving complete responses, two of whom received a combination of azer-cel with lymphodepletion and interleukin-2 (IL-2), showing durable responses extending beyond 90 and 120 days.

The company has also dosed the first patient in the intratumoural (IT) injection combination arm of its OASIS Phase 1 clinical trial for onCARlytics (CF33-CD19).

This trial aims to test the efficacy and safety of Imugene's CD19-expressing oncolytic virotherapy in advanced or metastatic solid tumours. The first colorectal cancer patient was treated at Northwestern University, and the trial is expected to enrol up to 40 participants with various advanced cancers.

#ProactiveInvestors #Imugene #ASX  #Oncology #CAR_TCellTherapy #AzerCel #Vaxinia #ClinicalTrials #CancerResearch #Immunotherapy #DLBCL #HER2 #BileCancer #Biotechnology #ASX #FDAApproval #OrphanDrug #FastTrack #BiotechInvesting #OncolyticVirotherapy #CancerTreatment #CashPosition

Far East Gold Ltd (ASX:FEG, OTC:FEGDF) CEO Shane Menere joins Proactive’s Tylah Tully to discuss the first $6.4 million tranche the company has received from Xingye Gold (Hong Kong) Mining Company Limited, marking a significant step in a strategic investment agreement.

Xingye Gold, a subsidiary of Inner Mongolia Xingye Silver & Tin Mining Co. Ltd, has secured all necessary Chinese regulatory approvals, enabling the transfer of A$6,391,669.60 to FEG.

This tranche is part of a three-stage conditional share placement valued at more than A$14 million, aiming to provide Xingye with a 19.99% stake in FEG at A$0.20 per share, a 47% premium over recent pricing.

Menere highlighted this investment as a pivotal milestone, aligning with recent strategic acquisitions and strengthening the company’s access to funding, technical expertise and partnership opportunities.

Xingye, China’s largest silver producer with a Shenzhen Stock Exchange listing and market capitalisation exceeding A$4 billion, brings experience in progressing greenfield mining projects to production.

This collaboration supports FEG’s goal of advancing its asset portfolio through to production, with provisions for potential future investments.

#ProactiveInvestors #FarEastGold #ASX #OTC #Xingye #MiningInvestment #GoldMining #StrategicPartnership #ASX #SilverProduction #MiningIndustry #GreenfieldProjects #NaturalResources #ChinaMining #CorporateInvestment #GoldExploration #MiningNews #FinancialMilestone #ShenzhenStockExchange #InvestmentTranche #TechnicalExpertise #AssetDevelopment #CapitalRaising

Far East Gold receives $6.4 million from Xingye

Zenith Minerals (ASX:ZNC) managing director Andrew Smith talked with Proactive’s Tylah Tully about the company's ongoing efforts to expand its gold resources and outline its unique investor appeal.

The company is focused on advancing its flagship projects, including Dulcie Far North in Western Australia and Red Mountain in Queensland.

According to Smith, these projects hold significant growth potential, especially as the company aims to achieve a 600,000–700,000-ounce target from Dulcie Far North through organic growth, new drilling and potential asset acquisitions.

Smith highlighted the recent drilling efforts, including a 17-hole program aimed at expanding and confirming the inferred resources at Dolce Far North.

While final data from the program is still pending, early results appear promising.

He encouraged stakeholders to "watch this space for an announcement soon”.

Moving forward, Zenith is continuing work on the Red Mountain project, which has already shown significant potential and could evolve into a larger-scale operation.

This year, the company plans a 20-hole drilling program there, aiming to explore the system’s potential despite the associated risk.

In discussing Zenith’s investor case, Smith emphasised the company’s low current valuation, which he views as an attractive entry point for potential investors.

"We have a big pipeline of exploration work ahead of us," he stated, adding that Zenith’s portfolio covers both early-stage gold exploration and longer-term interests in lithium.

#ProactiveInvestors #ZenithMinerals #ASX #GoldExploration #DolceFarNorth #RedMountainProject #MiningInvesting #AndrewSmith #ProactiveInvestors #GoldResources #LithiumProjects #InvestorUpdates

Gold Hydrogen Ltd (ASX:GHY) managing director Neil McDonald joins Proactive’s Tylah Tully to discuss the company’s expanded exploration footprint in South Australia.

It has been awarded a new petroleum licence (PELA 792), adding approximately 1,900 square kilometres to its exploration footprint, which now spans 77,292 square kilometres.

The licence includes three areas, one adjacent to PELA 688, held by subsidiary Byrock Resources Pty Ltd, and two sections on the Eyre Peninsula, close to the state’s planned hydrogen power infrastructure in Whyalla and Port Bonython.

The South Australian Government’s Hydrogen Jobs Plan allocates A$500 million for a 200-megawatt hydrogen power plant and electrolyser near Whyalla, anticipated to be operational by early 2026.

Additionally, the Port Bonython Hydrogen Hub, in collaboration with private industry, will support renewable hydrogen production, enhancing South Australia's hydrogen export capacity.

#ProactiveInvestors #GoldHydrogen #ASX #Exploration #HydrogenPower #SouthAustralia #PELA792 #RenewableEnergy #HydrogenJobsPlan #NaturalHydrogen #HeliumExploration #Whyalla #PortBonython #ASX #ResourceExploration #GreenEnergy #EnergyTransition #HydrogenHub #SustainableMining #CleanEnergy #EnvironmentalStewardship #EnergyStorage

Caledonia Mining Corporation PLC chief executive Mark Learmonth takes Proactive's Stephen Gunnion through the company's progress in the third quarter and future plans.

Learmonth highlighted that while the production remained on track, operational costs at Blanket Mine were high, driven by electricity and labour. The company is working to cut these costs significantly in the coming quarters.

Learmonth discussed exploration at the Motapa Gold Project, sharing that the results were encouraging, with notable drill intersections reaching up to 11g per ton. The company is also focused on a feasibility study for the Bilboes sulfide project, expected by early next year, and considering funding combinations involving debt and equity.

Additionally, Learmonth explained the strategic decision to sell Blanket's solar plant for $22 million, emphasising capital efficiency for future investments.

Caledonia's goals include reducing costs, finalising feasibility studies, and maintaining exploration momentum to extend its development pipeline.

For more updates and detailed insights, visit Proactive's YouTube channel, like the video, subscribe, and enable notifications for future content.

#CaledoniaMining #GoldProduction #MarkLearmonth #MiningUpdates #GoldExploration #BilboesProject #MotapaGold #CostReduction #ProactiveInterviews

#ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews